Chronic Inflammatory Demyelinating Polyradiculoneuropathy: From Bench to Bedside

Amanda C. Peltier; Peter D. Donofrio

doi:10.1055/s-0032-1329194

Seminars in Neurology, Table of Contents

Semin Neurol 2012; 32(03): 187-195
DOI: 10.1055/s-0032-1329194

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: From Bench to Bedside

Authors

Amanda C. Peltier

¹Department of Neurology, Vanderbilt Medical Center, Medical Center North, Nashville, Tennessee
Peter D. Donofrio

¹Department of Neurology, Vanderbilt Medical Center, Medical Center North, Nashville, Tennessee

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common treatable chronic autoimmune neuropathy. Multiple diagnostic criteria have been established, with the primary goal of identifying neurophysiologic hallmarks of acquired demyelination. Treatment modalities have expanded to include numerous immunomodulatory therapies, although the best evidence continues to be for corticosteroids, plasma exchange, and intravenous immunoglobulin (IVIg). This review describes the pathology, epidemiology, pathogenesis, diagnosis, and treatment of CIDP.

Keywords

CIDP - demyelination - inflammatory neuropathy

Full Text

References

References
1 Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50 (11) 621-637
2 Burns TM. Chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2004; 61 (6) 973-975
3 Austin JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 1958; 81 (2) 157-192
4 Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54 (3) 615-620
5 Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32 (9) 958-964
6 Oh SJ, Joy JL, Kuruoglu R. “Chronic sensory demyelinating neuropathy”: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992; 55 (8) 677-680
7 Pestronk A, Cornblath DR, Ilyas AA , et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988; 24 (1) 73-78
8 Kelly Jr JJ. The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve 1983; 6 (7) 504-509
9 Cocito D, Durelli L, Isoardo G. Different clinical, electrophysiological and immunological features of CIDP associated with paraproteinaemia. Acta Neurol Scand 2003; 108 (4) 274-280
10 McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987; 110 (Pt 6) 1617-1630
11 Gabriel CM, Hughes RA, Moore SE, Smith KJ, Walsh FS. Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Brain 1998; 121 (Pt 10) 1895-1902
12 Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2006; 11 (1) 30-46
13 Kuwahara M, Suzuki S, Takada K, Kusunoki S. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 2011; 239 (1-2) 87-90
14 Chi LJ, Xu WH, Zhang ZW, Huang HT, Zhang LM, Zhou J. Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010; 15 (4) 345-356
15 Archelos JJ, Mäurer M, Jung S , et al. Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1. Lab Invest 1994; 70 (5) 667-675
16 Kieseier BC, Tani M, Mahad D , et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002; 125 (Pt 4) 823-834
17 Mahad DJ, Howell SJ, Woodroofe MN. Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002; 73 (3) 320-323
18 Mei FJ, Ishizu T, Murai H , et al. Th1 shift in CIDP versus Th2 shift in vasculitic neuropathy in CSF. J Neurol Sci 2005; 228 (1) 75-85
19 Meléndez-Vásquez C, Redford J, Choudhary PP , et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 1997; 73 (1-2) 124-134
20 Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996; 19 (4) 474-487
21 Kiefer R, Dangond F, Mueller M, Toyka KV, Hafler DA, Hartung HP. Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies. J Neurol Neurosurg Psychiatry 2000; 69 (3) 362-368
22 Van Rhijn I, Van den Berg LH, Bosboom WM, Otten HG, Logtenberg T. Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. Brain 2000; 123 (Pt 10) 2020-2029
23 Murata K, Dalakas MC. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain 2000; 123 (Pt 8) 1660-1666
24 Zivković SA, Peltier AC, Iacob T, Lacomis D. Chronic inflammatory demyelinating polyneuropathy and ventilatory failure: report of seven new cases and review of the literature. Acta Neurol Scand 2011; 124 (1) 59-63
25 Figueroa JJ, Dyck PJ, Laughlin RS , et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78 (10) 702-708
26 Laughlin RS, Dyck PJ, Melton III LJ, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73 (1) 39-45
27 Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009; 39 (4) 432-438
28 McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46 (6) 910-913
29 Iijima M, Koike H, Hattori N , et al; Refractory Peripheral Neuropathy Study Group of Japan. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008; 79 (9) 1040-1043
30 Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999; 66 (5) 677-680
31 Simpson DM, Olney RK. Peripheral neuropathies associated with human immunodeficiency virus infection. Neurol Clin 1992; 10 (3) 685-711
32 Brannagan III TH, Zhou Y. HIV-associated Guillain-Barré syndrome. J Neurol Sci 2003; 208 (1-2) 39-42
33 Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995; 118 (Pt 2) 359-368
34 Tackenberg B, Lünemann JD, Steinbrecher A , et al. Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 2007; 68 (19) 1622-1629
35 Wadwekar V, Kalita J, Misra UK. Does the chronic inflammatory demyelinating polyradiculoneuropathy due to secondary cause differ from primary?. Neurol India 2011; 59 (5) 664-668
36 Larue S, Bombelli F, Viala K , et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 2011; 18 (6) 899-905
37 Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch Neurol 2003; 60 (2) 260-264
38 Mendell JR, Kolkin S, Kissel JT, Weiss KL, Chakeres DW, Rammohan KW. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1987; 37 (8) 1291-1294
39 Gigli GL, Carlesimo A, Valente M , et al. Evoked potentials suggest cranial nerves and CNS involvement in chronic relapsing polyradiculoneuropathy. Eur Neurol 1989; 29 (3) 145-149
40 Ohtake T, Komori T, Hirose K, Tanabe H. CNS involvement in Japanese patients with chronic inflammatory demyelinating polyradiculoneuropathy. Acta Neurol Scand 1990; 81 (2) 108-112
41 Uncini A, Gallucci M, Lugaresi A, Porrini AM, Onofrj M, Gambi D. CNS involvement in chronic inflammatory demyelinating polyneuropathy: an electrophysiological and MRI study. Electromyogr Clin Neurophysiol 1991; 31 (6) 365-371
42 Berger AR, Herskovitz S, Kaplan J. Late motor involvement in cases presenting as “chronic sensory demyelinating polyneuropathy”. Muscle Nerve 1995; 18 (4) 440-444
43 Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJ. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 2004; 63 (9) 1662-1669
44 Larue S, Bombelli F, Viala K , et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 2011; 18 (6) 899-905
45 Remiche G, Kentos A, Mavroudakis N. Distal acquired demyelinating symmetric neuropathy associated with anti-GM1 antibodies: is this a CIDP variant?. Acta Neurol Belg 2010; 110 (1) 103-106
46 Sander HW, Latov N. Research criteria for defining patients with CIDP. Neurology 2003; 60 (8) (Suppl. 03) S8-S15
47 Hughes R, Bensa S, Willison H , et al; Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50 (2) 195-201
48 Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41 (5) 617-618
49 Bromberg MB. Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2011; 43 (6) 780-794
50 Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1985; 8 (6) 528-539
51 Albers JW, Kelly Jr JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989; 12 (6) 435-451
52 Sander HW, Latov N. Research criteria for defining patients with CIDP. Neurology 2003; 60 (8) (Suppl. 03) S8-S15
53 Nicolas G, Maisonobe T, Le Forestier N, Léger JM, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002; 25 (1) 26-30
54 Haq RU, Fries TJ, Pendlebury WW, Kenny MJ, Badger GJ, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria. Arch Neurol 2000; 57 (12) 1745-1750
55 Thaisetthawatkul P, Logigian EL, Herrmann DN. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 2002; 59 (10) 1526-1532
56 Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24 (3) 311-324
57 Nicolas G, Maisonobe T, Le Forestier N, Léger JM, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002; 25 (1) 26-30
58 Wilson J, Chawla J, Fisher M. Sensitivity and specificity of electrodiagnostic criteria for CIDP using ROC curves: comparison to patients with diabetic and MGUS associated neuropathies. J Neurol Sci 2005; 231 (1-2) 19-28
59 Wilson JR, Park Y, Fisher MA. Electrodiagnostic criteria in CIDP: comparison with diabetic neuropathy. Electromyogr Clin Neurophysiol 2000; 40 (3) 181-185
60 Latov N. Diagnosis of CIDP. Neurology 2002; 59 (1) (2) (Suppl. 06) S2-S6
61 Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989; 46 (8) 878-884
62 Hattori N, Misu K, Koike H , et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001; 184 (1) 57-63
63 Hahn AF, Hartung H, Dyck PJ. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, , eds. Peripheral Neuropathy. 4th ed. Philadelphia: Elsevier Saunders; 2005: 2221-2253
64 Chimowitz MI, Audet AM, Hallet A, Kelly Jr JJ. HIV-associated CIDP. Muscle Nerve 1989; 12 (8) 695-696
65 Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001; 115 (1-2) 4-18
66 Kalita J, Misra UK, Yadav RK. A comparative study of chronic inflammatory demyelinating polyradiculoneuropathy with and without diabetes mellitus. Eur J Neurol 2007; 14 (6) 638-643
67 Sommer C, Toyka K. Nerve biopsy in chronic inflammatory neuropathies: in situ biomarkers. J Peripher Nerv Syst 2011; 16 (Suppl. 01) 24-29
68 Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996; 19 (4) 474-487
69 Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka KV. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 2005; 65 (12) 1924-1929
70 Bromberg MB, Albers JW. Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders. Muscle Nerve 1993; 16 (3) 262-266
71 Saporta MA, Katona I, Lewis RA, Masse S, Shy ME, Li J. Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A. Brain 2009; 132 (Pt 12) 3263-3273
72 Taylor BV, Dyck PJ, Engelstad J, Gruener G, Grant I, Dyck PJ. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol 2004; 63 (2) 129-137
73 Dalakas MC. Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011; 7 (9) 507-517
74 Dyck PJ, O'Brien PC, Oviatt KF , et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11 (2) 136-141
75 Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981; 9 (Suppl) 134-145
76 van Schaik IN, Eftimov F, van Doorn PA, , et al; van S. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9 (3) 245-253
77 Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN. PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012; 78 (14) 1079-1084
78 Mendell JR, Barohn RJ, Freimer ML , et al; Working Group on Peripheral Neuropathy. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56 (4) 445-449
79 Hughes RA, Donofrio P, Bril V , et al; ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7 (2) 136-144
80 Donofrio PD, Bril V, Dalakas MC , et al; IGIV-C CIDP Efficacy (ICE) Study Group. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67 (9) 1082-1088
81 Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009; (1) CD001797
82 Iijima M, Koike H, Sobue G. [Efficacy and availability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy]. Nihon Rinsho 2012; 70 (4) 715-721
83 Cocito D, Serra G, Falcone Y, Paolasso I. The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin. J Peripher Nerv Syst 2011; 16 (2) 150-152
84 Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology 1985; 35 (8) 1096-1104
85 Dyck PJ, Daube J, O'Brien P , et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314 (8) 461-465
86 Hahn AF, Bolton CF, Pillay N , et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119 (Pt 4) 1055-1066
87 Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004; (3) CD003906
88 Galldiks N, Burghaus L, Dohmen C , et al. Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. Eur Neurol 2011; 66 (4) 183-189
89 Dyck PJ, Litchy WJ, Kratz KM , et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36 (6) 838-845
90 Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48 (2) 321-328
91 Cocito D, Paolasso I, Antonini G , et al; Italian Network for CIDP Register. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17 (2) 289-294
92 Dyck PJ, O'Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985; 35 (8) 1173-1176
93 Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 51 (6) 1735-1738
94 Brannagan III TH, Pradhan A, Heiman-Patterson T , et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002; 58 (12) 1856-1858
95 Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998; 21 (4) 454-460
96 Mahattanakul W, Crawford TO, Griffin JW, Goldstein JM, Cornblath DR. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 1996; 60 (2) 185-187
97 Takeuchi A, Shirai S, Horiuchi K , et al. [Successful cyclosporine treatment in 2 patients with refractory CIDP, involving monitoring of both AUC(0-4h) and trough levels]. Rinsho Shinkeigaku 2012; 52 (3) 172-177
98 Visudtibhan A, Chiemchanya S, Visudhiphan P. Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. Pediatr Neurol 2005; 33 (5) 368-372
99 Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001; 56 (1) 94-96
100 Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001; 185 (2) 119-122
101 Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004; 63 (4) 715-717
102 Umapathi T, Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 2002; 9 (6) 683-685
103 RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8 (2) 158-164
104 Benedetti L, Briani C, Franciotta D , et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82 (3) 306-308
105 Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35 (1) 66-69
106 Benedetti L, Franciotta D, Beronio A , et al. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle Nerve 2008; 38 (2) 1076-1077
107 Sanz PG, García Méndez CV, Cueto AL , et al. Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment. Rheumatol Int 2011; ; Epub ahead of print
108 D'Amico A, Catteruccia M, De Benedetti F , et al. Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. Eur J Paediatr Neurol 2012; 16 (3) 301-303
109 Brannagan III TH, Patterson SK. Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment?. Expert Rev Clin Immunol 2010; 6 (3) 319-321
110 Marsh EA, Hirst CL, Llewelyn JG , et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010; 257 (6) 913-919
111 Sabatelli M, Mignogna T, Lippi G , et al. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1995; 58 (5) 638-639
112 Gorson KC, Ropper AH, Clark BD, Dew III RB, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998; 50 (1) 84-87
113 Choudhary PP, Thompson N, Hughes RA. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995; 242 (4) 252-253
114 Vallat JM, Hahn AF, Léger JM , et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003; 60 (8) (Suppl. 03) S23-S28
115 Villa AM, Garcea O, Di Egidio M, Saizar R, Sica RE. Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report. Arq Neuropsiquiatr 2004; 62 (3B) 892-894
116 Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999; 53 (1) 57-61
117 Kuntzer T, Radziwill AJ, Lettry-Trouillat R , et al. Interferon-beta1a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999; 53 (6) 1364-1365
118 Hughes RA, Gorson KC, Cros D , et al; Avonex CIDP Study Group. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010; 74 (8) 651-657
119 Cocito D, Grimaldi S, Paolasso I , et al; Italian Network for CIDP Register. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol 2011; 18 (12) 1417-1421
120 Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004; (4) CD003280
121 Mahdi-Rogers M, Kazmi M, Ferner R , et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst 2009; 14 (2) 118-124
122 Brannagan III TH. Current diagnosis of CIDP: the need for biomarkers. J Peripher Nerv Syst 2011; 16 (Suppl. 01) 3-13
123 Latov N. Biomarkers of CIDP in patients with diabetes or CMT1. J Peripher Nerv Syst 2011; 16 (Suppl. 01) 14-17
124 Willison HJ. Biomarkers in experimental models of antibody-mediated neuropathies. J Peripher Nerv Syst 2011; 16 (Suppl. 01) 60-62